{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"955","value":"493"},{"groupId":"OG001","spread":"2011","value":"1252"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Average Reduction in IgM Protein mg/dL from Cycle 1 thru Study","dispersionType":"Standard Deviation","groups":[{"description":"2mg Pomolidomide per day per Cycle (Cycle = 28 days)","id":"OG000","title":"Cohort 2"},{"description":"1mg Pomolidomide per day per Cycle (Cycle = 28 days)","id":"OG001","title":"Cohort 3"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Through Study Completion (Avg. 1 Year)","title":"Changes in Waldestrom Biomarkers","type":"SECONDARY","unitOfMeasure":"IgM Protein mg/dL"}